Breaking News Instant updates and real-time market news.

ABMD

Abiomed

$119.79

-0.94 (-0.78%)

, MDT

Medtronic

$81.54

-0.32 (-0.39%)

07:47
03/07/17
03/07
07:47
03/07/17
07:47

FDA Pediatric Advisory Committee to hold a meeting

The Committee discusses pediatric-focused safety reviews, as mandated by The FDA Safety and Innovation Act (FDASIA), for Novo Nordisk's NOVOEIGHT (Antihemophilic Factor ) and Shire's RIXUBIS Coagulation Factor IX (Recombinant). Additionally, The Committee discusses the safety of and the ongoing propriety of the humanitarian device exemption for Vericel's EPICEL (cultured epidermal autografts) (HDE), Abiomed's IMPELLA RP SYSTEM (HDE), Kaneka's LIPOSORBER LA-15 SYSTEM (HDE) and Medtronic's MEDTRONIC ACTIVA DYSTONIA THERAPY (HDE). The meeting is being held in Silver Spring MD on March 7 at 8:30 am. Webcast Link

ABMD

Abiomed

$119.79

-0.94 (-0.78%)

MDT

Medtronic

$81.54

-0.32 (-0.39%)

NVO

Novo Nordisk

$33.92

-0.76 (-2.19%)

SHPG

Shire

$184.48

-1.82 (-0.98%)

VCEL

Vericel

$2.85

-0.05 (-1.72%)

  • 07

    Mar

  • 07

    Mar

  • 10

    Mar

  • 14

    Mar

  • 14

    Mar

  • 17

    Mar

  • 21

    Mar

  • 23

    Mar

  • 24

    Mar

  • 01

    Apr

  • 26

    Jun

ABMD Abiomed
$119.79

-0.94 (-0.78%)

12/07/16
12/07/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Micron (MU) initiated with a Buy at Citi. 2. Owens Corning (OC) initiated with a Buy at Seaport Global. 3. Abiomed (ABMD) initiated with a Buy at Guggenheim. 4. ZELTIQ (ZLTQ) initiated with a Buy at Aegis. 5. Navient (NAVI) initiated with a Hold at Jefferies. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
12/07/16
GUGG
12/07/16
INITIATION
Target $150
GUGG
Buy
Abiomed initiated with a Buy at Guggenheim
Guggenheim analyst Christopher Pasquale initiated Abiomed with a Buy and a $150 price target.
12/06/16
GUGG
12/06/16
INITIATION
GUGG
Buy
Abiomed initiated with a Buy at Guggenheim
11/18/16
LEER
11/18/16
NO CHANGE
Target $140
LEER
Outperform
Abiomed remains on 'hyper-growth trajectory,' says Leerink
After hosting investor meetings with the company's CEO Mike Minogue, CFO Mike Tomsicek, and Director of IR Ingrid Goldberg, Leerink analyst Danielle Antalffy remains confident that Abiomed's fundamentals are intact, and the company remains on a "hyper-growth trajectory" with significant positive operating leverage. The analyst remains confident in a sustainable long-term "strong" double-digit growth trajectory built on a market-leading product, a large and still-expanding salesforce, and a "strong" foundation of clinical evidence. She reiterates an Outperform rating and $140 price target on the shares.
MDT Medtronic
$81.54

-0.32 (-0.39%)

02/14/17
WELS
02/14/17
NO CHANGE
WELS
Medtronic data likely to be positive, says Wells Fargo
Wells Fargo predicts that data on Medtronic's (MDT) CoreValve/Evolut R, due to be presented on March 17, will show that the device "is superior to surgical aortic valve replacement in intermediate risk patients." If the results come in as expected, the device should be approved in the U.S. by early fall, according to the firm. Wells Fargo adds that the data should also be a positive for other TAVR stocks, including Edwards Lifesciences (EW) and Boston Scientific (BSX). Wells keeps Outperform ratings on all three stocks.
02/15/17
DBAB
02/15/17
NO CHANGE
Target $96
DBAB
Buy
Medtronic shares have more upside, says Deutsche Bank
Deutsche Bank analyst Kristen Stewart says the recent stock appreciation has not changed her bullish view on Medtronic. Ahead of the company's Q3 results on February 21, Stewart sees more upside in the stock. She keeps a Buy rating on Medtronic with a $96 price target.
02/22/17
NEED
02/22/17
NO CHANGE
Target $91
NEED
Buy
Medtronic price target raised to $91 from $84 at Needham
Needham analyst Mike Matson raised his price target for Medtronic to $91 from $84 after Q3 revenue and EPS beat consensus and the company maintained its 2017 guidance. The analyst believes the shares remain at a discount to peers and reiterates a Buy rating on the stock.
02/23/17
LEER
02/23/17
NO CHANGE
Target $85
LEER
Market Perform
Medtronic price target raised to $85 from $80 at Leerink
Leerink analyst Danielle Antalffy raised her price target for Medtronic to $85 from $80 after the company delivered what he believes was an "encouraging rebound" quarter after an unexpected Q2 miss. While the analyst remains cautious on the company's ability to manage through what could be meaningful top-line headwinds in Q4 and FY18 in order to deliver a targeted mid-single-digit sales growth, it does seem that the diversified business model gives it a cushion with which to offset underperforming business segments with stronger/faster growth elsewhere. He reiterates a Market Perform rating on the shares.
NVO Novo Nordisk
$33.92

-0.76 (-2.19%)

02/02/17
DBAB
02/02/17
NO CHANGE
DBAB
Novo Nordisk added to short-term buy list at Deutsche Bank
01/04/17
JPMS
01/04/17
DOWNGRADE
JPMS
Underweight
Novo Nordisk downgraded to Underweight from Neutral at JPMorgan
JPMorgan analyst Richard Vosser downgraded Novo Nordisk yesterday to Underweight saying consensus expectations are not reflecting the potential for further pricing pressure in the U.S. The analyst has a DKR 225 price target for the shares.
01/03/17
JPMS
01/03/17
DOWNGRADE
JPMS
Underweight
Novo Nordisk downgraded to Underweight from Neutral at JPMorgan
12/15/16
HCWC
12/15/16
NO CHANGE
Target $13
HCWC
Buy
vTv Therapeutics Phase 2 diabetes data a 'big win,' says H.C. Wainwright
H.C. Wainwright analyst Corey Davis views vTv Therapeutics' (VTVT) data from its Phase 2 study of TTP273 in type-2 diabetes as "very positive" and a "big win." Efficacy is close to Novo Nordisk's (NVO) oral semaglutide, Davis tells investors in a research note. vTv is "highly likely" to succeed in finding a partner given the attractiveness of the diabetes market and the differentiated profile '273 has now created, the analyst contends. Davis keeps a Buy rating on the shares with a $13 price target.
SHPG Shire
$184.48

-1.82 (-0.98%)

12/02/16
SOCG
12/02/16
INITIATION
SOCG
Buy
Shire initiated with a Buy at Societe Generale
12/02/16
12/02/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top analyst initiations with this list compiled by The Fly: 1. Exxon Mobil (XOM) initiated at BMO Capital. 2. Pfizer (PFE) initiated with a Neutral at Guggenheim. 3. DuPont Fabros (DFT) initiated with a Neutral at Guggenheim. 4. Acadia (ACHC) resumed with a Buy at Jefferies. 5. Shire (SHPG) initiated with a Buy at Societe Generale. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
01/19/17
01/19/17
NO CHANGE

Shire's application for ADHD disorder candidate acknowledged by FDA
Shire announced that the FDA has acknowledged receipt of the Class 2 resubmission of a New Drug Application for SHP465, a long-acting, triple-bead, mixed amphetamine salts formulation. SHP465 is being evaluated as a potential once-daily treatment for Attention-Deficit/Hyperactivity Disorder. The FDA is expected to provide a decision on or around June 20. Shire resubmitted the NDA for SHP465 in response to the Approvable Letter from the FDA that requested additional clinical studies and classified the response as a Class 2 resubmission with a review goal of six months. Launch is planned for the second half of 2017.
12/06/16
UBSW
12/06/16
DOWNGRADE
UBSW
Neutral
Shire downgraded to Neutral from Buy at UBS
VCEL Vericel
$2.85

-0.05 (-1.72%)

03/10/16
LTCO
03/10/16
NO CHANGE
Target $8.45
LTCO
Buy
Vericel Phase IIb trial success a surprise, says Ladenburg
Ladenburg analyst Kevin DeGeeter said he and, in his view, most investors, had low expectations for Vericel's Phase IIb study of ixmyelocel-T in advanced heart failure patients due to ischemic dilated cardiomyopathy, or DCM. DeGeeter noted that he didn't have any value for DCM in his valuation and will reevaluate following the company's release of full data in early April. The analyst reiterates a Buy rating and $8.45 price target on Vericel shares, which are up 89% to $4.00 in afternoon trading.
12/22/16
PIPR
12/22/16
INITIATION
Target $6
PIPR
Overweight
Vericel initiated with an Overweight at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff initiated Vericel with an Overweight rating and $6 price target, saying he sees the company's recently approved Matrix-induced Autologous Chondrocyte Implant to drive cartilage repair growth. Tenthoff predicts combined knee ACI sales growth of 23.3% to $44.5M in 2017 and then MACI growth of 21% to $54M in 2018.
03/11/16
NEED
03/11/16
UPGRADE
NEED
Buy
Vericel upgraded to Buy from Hold at Needham

TODAY'S FREE FLY STORIES

PVH

PVH Corp.

$98.68

7.83 (8.62%)

, F

Ford

$11.72

-0.05 (-0.42%)

12:21
03/23/17
03/23
12:21
03/23/17
12:21
General news
On The Fly: Top stock stories at midday »

Stocks opened lower as…

PVH

PVH Corp.

$98.68

7.83 (8.62%)

F

Ford

$11.72

-0.05 (-0.42%)

DIS

Disney

$112.76

0.68 (0.61%)

FEYE

FireEye

$11.49

0.05 (0.44%)

FIVE

Five Below

$38.13

-0.72 (-1.85%)

ONDK

On Deck Capital

$4.86

0.38 (8.48%)

PFPT

Proofpoint

$79.20

0.93 (1.19%)

ACN

Accenture

$121.92

-4.56 (-3.61%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Mar

  • 23

    Mar

  • 23

    Mar

  • 23

    Mar

  • 23

    Mar

  • 27

    Mar

  • 27

    Mar

  • 28

    Mar

  • 27

    Apr

  • 09

    May

  • 20

    Jun

12:20
03/23/17
03/23
12:20
03/23/17
12:20
General news
FX Action: USD-JPY has bounced »

FX Action: USD-JPY has…

GCI

Gannett

$8.21

0.09 (1.11%)

12:20
03/23/17
03/23
12:20
03/23/17
12:20
Conference/Events
Gannett management to meet with Stephens »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    May

$NSD

NASDAQ Market Internals

12:17
03/23/17
03/23
12:17
03/23/17
12:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TISA

Top Image Systems

$1.24

-0.0212 (-1.68%)

12:16
03/23/17
03/23
12:16
03/23/17
12:16
Hot Stocks
Breaking Hot Stocks news story on Top Image Systems »

Palogic Capital reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

12:16
03/23/17
03/23
12:16
03/23/17
12:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

12:15
03/23/17
03/23
12:15
03/23/17
12:15
General news
Treasury Action: bonds are in limbo awaiting results the House ACA vote »

Treasury Action: bonds…

12:15
03/23/17
03/23
12:15
03/23/17
12:15
General news
Breaking General news story  »

Minneapolis Federal…

Z

Zillow

$35.29

0.12 (0.34%)

12:11
03/23/17
03/23
12:11
03/23/17
12:11
Options
Bearish flow in Zillow as shares falter »

Bearish flow in Zillow as…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    May

12:10
03/23/17
03/23
12:10
03/23/17
12:10
General news
U.S. equities are dusting themselves off »

U.S. equities are dusting…

ATEC

Alphatec

$2.68

-0.12 (-4.29%)

12:08
03/23/17
03/23
12:08
03/23/17
12:08
Syndicate
Alphatec announces $18.9M private placement »

H.C. Wainwright is acting…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OA

Orbital ATK

$99.47

-0.075 (-0.08%)

12:08
03/23/17
03/23
12:08
03/23/17
12:08
Periodicals
SSL sues Orbital ATK over claims of confidential data theft, Reuters says »

Space Systems/Loral has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Mar

TRIP

TripAdvisor

$41.40

-0.31 (-0.74%)

, PCLN

Priceline

$1,751.99

4.85 (0.28%)

12:06
03/23/17
03/23
12:06
03/23/17
12:06
Hot Stocks
TripAdvisor strength attributed to takeover speculation »

The intraday move up in…

TRIP

TripAdvisor

$41.40

-0.31 (-0.74%)

PCLN

Priceline

$1,751.99

4.85 (0.28%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

12:01
03/23/17
03/23
12:01
03/23/17
12:01
Conference/Events
Stephens transportation analysts hold an analyst/industry conference call »

Transportation Analysts…

BAC

Bank of America

$23.34

0.4 (1.74%)

12:01
03/23/17
03/23
12:01
03/23/17
12:01
Options
Today's four most active single stock options are calls on BofA »

Today's four most…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LMT

Lockheed Martin

$270.93

1.51 (0.56%)

12:01
03/23/17
03/23
12:01
03/23/17
12:01
Hot Stocks
Lockheed Martin to expand production for F-35 components in Johnstown »

Lockheed Martin will…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Mar

CEO

CNOOC

$118.68

3.25 (2.82%)

11:59
03/23/17
03/23
11:59
03/23/17
11:59
Upgrade
CNOOC rating change  »

CNOOC upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

POL

PolyOne

$33.38

0.47 (1.43%)

11:59
03/23/17
03/23
11:59
03/23/17
11:59
Conference/Events
PolyOne management to meet with Jefferies »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Mar

  • 27

    Mar

GRBK

Green Brick

11:56
03/23/17
03/23
11:56
03/23/17
11:56
Hot Stocks
Green Brick Partners director acquires 20,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FLXN

Flexion

$19.68

0.14 (0.72%)

, SNY

Sanofi

$45.09

0.42 (0.94%)

11:56
03/23/17
03/23
11:56
03/23/17
11:56
Recommendations
Flexion, Sanofi analyst commentary  »

Flexion CFO departure…

FLXN

Flexion

$19.68

0.14 (0.72%)

SNY

Sanofi

$45.09

0.42 (0.94%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Mar

  • 29

    Mar

  • 10

    May

  • 06

    Oct

SAN

Banco Santander

$6.12

0.005 (0.08%)

11:55
03/23/17
03/23
11:55
03/23/17
11:55
Hot Stocks
Santander to improve consumer protections in Fed agreement »

Santander has agreed to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:55
03/23/17
03/23
11:55
03/23/17
11:55
Conference/Events
Federal Reserve Bank of Minneapolis President speaks at conference »

Minneapolis Federal…

MAA

MAA

$101.99

0.72 (0.71%)

11:54
03/23/17
03/23
11:54
03/23/17
11:54
Conference/Events
MAA management to meet with Jefferies »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Mar

  • 28

    Mar

ADP

ADP

$103.68

0.56 (0.54%)

, CSOD

Cornerstone OnDemand

$38.36

-0.14 (-0.36%)

11:53
03/23/17
03/23
11:53
03/23/17
11:53
Conference/Events
Stephens enterprise software analysts hold an analyst/industry conference call »

Enterprise Software…

ADP

ADP

$103.68

0.56 (0.54%)

CSOD

Cornerstone OnDemand

$38.36

-0.14 (-0.36%)

ORCL

Oracle

$44.97

0.175 (0.39%)

PAYC

Paycom

$54.22

-1.06 (-1.92%)

PCTY

Paylocity

$35.16

-0.16 (-0.45%)

SAP

SAP

$98.09

0.44 (0.45%)

ULTI

Ultimate Software

$193.35

1.24 (0.65%)

WDAY

Workday

$81.64

0.19 (0.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

  • 09

    May

  • 08

    Jun

  • 20

    Jun

TRP

TransCanada

$46.42

0.25 (0.54%)

11:52
03/23/17
03/23
11:52
03/23/17
11:52
Periodicals
State Department expected to approve Keystone XL pipeline permit, Politico says »

The U.S. State Department…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.